Nestle India JV Partner Sent FSSAI Notice Over Claims Regarding Celevida GLP+

Market snapshot: The Food Safety and Standards Authority of India has issued show-cause notices to Dr. Reddy's, Nestle Health Science, Amazon, and Flipkart over allegedly misleading health and advertising claims for the nutrition supplement Celevida GLP+. The product is marketed as high-protein support to help patients preserve lean muscle during GLP-1/GIP weight-loss therapies.

Data Snapshot

• Nestle India posted a consolidated net profit of ₹975 crore for Q1 FY27, representing a 48% increase year-on-year.
• Nestle India reported operations revenue of ₹6,378 crore in Q1 FY27, marking a 25% year-on-year growth.
• Nestle India acquired 49,000 equity shares in the joint venture, Dr. Reddy's and Nestle Health Science Limited, following a definitive agreement.

What's Changed

• FSSAI has cracked down on claims associated with Celevida GLP+, a product designed to target the emerging and lucrative GLP-1 weight-loss therapy nutrition support market.
• Previously, Nestle India and Dr. Reddy's had launched this product to cater to patients undergoing obesity and diabetes treatments.
• Now, the regulator has challenged the validity of their claims, alleging they mislead consumers about the supplement's clinical capabilities.

Key Takeaways

• FSSAI has flagged several health claims made by the Celevida GLP+ brand, such as 'helps maintain lean muscle' and 'support muscle strength', asserting they are non-compliant.
• The regulator stated that the brand name 'Celevida GLP+' itself creates a misleading association with GLP-1/GIP clinical therapies, and that disclaimers are insufficient to negate this.
• Other claims such as 'Imported from Europe for purity' and 'complete daily nourishment' were also deemed ambiguous and misleading.
• E-commerce giants Amazon and Flipkart, alongside manufacturer Tirupati Wellness and Netmeds, were also issued notices for hosting and distributing the product under these claims.

SAHI Perspective

Regulatory compliance in the nutraceutical space is tightening in India, as FSSAI steps up scrutinization of health claims. For Nestle India, which operates in the segment through its joint venture 'Dr. Reddy's and Nestlé Health Science Limited', this notice introduces immediate reputational and compliance risks. Coming closely on the heels of another FSSAI issue regarding its Low Fat Dairy Whitener, Nestlé India is facing heightened regulatory pressure across its product lines. Companies must prioritize strict compliance over aggressive health claims to preserve trust in premium health segments.

Market Implications

The regulatory notice may temporarily slow the rollout of new weight-loss support products in India's emerging nutraceutical space. While Dr. Reddy's and Nestle India had hoped to capitalize on the fast-growing GLP-1 ecosystem, this development highlights the high legal hurdles for clinical marketing. Nestle India's stock could face short-term volatility as the company manages multiple food-safety and advertising disputes with the FSSAI.

Trading Signals

Market Bias: Bearish

Back-to-back regulatory notices from FSSAI—one on the Celevida GLP+ brand and another on Nestle's Low Fat Dairy Whitener being declared unsafe—create a near-term sentiment overhang on Nestle India. Despite strong Q1 FY27 financial performance with a consolidated net profit of ₹975 crore, regulatory risks remain elevated.

Underweight: FMCG, Nutraceuticals

Trigger Factors:

• FSSAI's final decision or potential penalty on the Celevida GLP+ advertising inquiry.
• Further developments or appeals regarding the ban on Nestle's Low Fat Dairy Whitener.
• Quarterly financial results announcement for the second quarter scheduled for October 14, 2026.

Time Horizon: Near-term (0-3 months)

Industry Context

India's weight-loss drug and companion nutraceutical support market has grown rapidly, estimated to be worth over ₹1,400 crore within just one year of innovator brand entries. The market is projected to grow fivefold over the next five years. This rapid expansion has attracted multiple domestic drugmakers and FMCG players, prompting tighter oversight from FSSAI to prevent misleading advertising and ensure consumer safety.

Key Risks to Watch

• Regulatory penalties or litigation expenses arising from FSSAI show-cause notices.
• Reputational damage affecting the premium nutraceutical brand ecosystem developed by the Nestle-Dr. Reddy's JV.
• Distribution disruptions if e-commerce platforms restrict the sale of the flagged product.

Recent Developments

On October 3, 2026, FSSAI ordered an immediate ban on the sale of Nestlé India's 'Low Fat Dairy Whitener' after a sample collected from The Lalit Hotel in New Delhi was declared 'unsafe and substandard' due to non-compliance with phosphorus limit standards. Nestlé India has disputed the findings, stating that the product is fully compliant and that the FSSAI lab reports failed to account for naturally occurring phosphorus in milk ingredients.

Closing Insight

FSSAI's proactive stance on misleading nutraceutical claims reflects a broader structural shift toward consumer protection. While the weight-loss support market offers immense potential, FMCG and pharma players must align their branding with stringent regulatory norms to avoid legal setbacks.

High Performance Trading with SAHI.